IP Library Granted Patent US 10,016,447
Granted Patent B2
US 10,016,447 · App. 15/512,946 · Granted Jul 10, 2018

Pharmaceutical composition having improved content uniformity

Inventors: Priyank Patel (Ahmedabad, IN); Mayur Patel (Ahmedabad, IN); Mahendra Patel (Ahmedabad, IN); Balvir Singh (Ahmedabad, IN); Ashish Sehgal (Ahmedabad, IN)
Assignee: Intas Pharmaceuticals Ltd.
A61K31/675A61K9/209A61K9/2054A61K31/7068C07F9/65846
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,447
App. No.
15/512,946
Granted
Jul 10, 2018
Kind
B2
Abstract

This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Claims (10)

1. A pharmaceutical composition comprising cyclophosphamide and one or more pharmaceutically acceptable excipients, wherein cyclophosphamide has D90 particle size less than 100 microns.

2. The pharmaceutical composition according to claim 1 , wherein the said pharmaceutical composition further comprises one or more pharmaceutical active ingredients.

3. The pharmaceutical composition according to claim 2 , wherein the said pharmaceutical active ingredient is capecitabine or its pharmaceutically acceptable salts thereof.

4. The pharmaceutical composition according to claim 1 , wherein the said pharmaceutical composition is present in a solid oral dosage form comprising of monolayer tablet, bilayer tablet, multilayer tablet, film-coated tablet, powders, lozenges, sachets and hard gelatin capsules.

5. The pharmaceutical composition according to claim 4 , wherein the said pharmaceutical composition is in the form of bilayer tablet.

6. The pharmaceutical composition according to claim 5 , wherein the bilayer tablet comprises a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.

7. The pharmaceutical composition according to claim 5 , wherein the first layer comprises capecitabine in the amount of 10 to 1500 mg and one or more excipients, and the second layer comprises cyclophosphamide in the amount of 20 to 80 mg and one or more excipients.

8. The pharmaceutical composition according to claim 1 , wherein the said pharmaceutical composition have a content uniformity between 95% and 105% and acceptance value less than 15 as per USP <905> uniformity of dosage units.

9. A pharmaceutical composition comprising cyclophosphamide and capecitabine in the form of bilayer tablet, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients, wherein the cyclophosphamide has D90 particle size less than 100 microns.

10. A pharmaceutical composition comprising cyclophosphamide and capecitabine in the form bilayer tablet, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients, wherein the cyclophosphamide has D90 particle size less than 100 microns; wherein the said pharmaceutical composition have a content uniformity between 95% and 105% and acceptance value less than 15 as per USP <905> uniformity of dosage units.

Assignments (2)
ASSIGNEE ADDRESS CHANGE Recorded May 24, 2018
From: INTAS PHARMACEUTICALS LTD.
To: INTAS PHARMACEUTICALS LTD.
Reel/Frame 046228/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2017
From: PATEL, PRIYANK; PATEL, MAYUR; PATEL, MAHENDRA; SINGH, BALVIR; SEHGAL, ASHISH
To: INTAS PHARMACEUTICALS LTD.
Reel/Frame 041667/0836 →
Priority Claims (1)
IN 3087/MUM/2014 · Sep 26, 2014 · national
Continuity (1)
Related Publication 20170304328A1 · Oct 26, 2017
Cited By (1)
US 12,453,737